Home / Market News / $PALI
benzinga Corporate Catalyst Impact 65/100 ● negative

Palisade Bio Announces Findings Presented At United European Gastroenterology Week; Five-Patient Phase 1B Crohn’s Disease Cohort Showed 47.5% Reduction In Mean Endoscopic Disease Activity And 58.8% Reduction In Mean Fecal Calprotectin After 14 Days; Phase 2b ASCENTRA-UC Study Is Enrolling; Phase 2a Crohn’s Disease Study Being Initiated

Oct 20, 2026, 12:09 PM UTC · Primary ticker $PALI

Palisade Bio presented promising Phase 1b data for PALI-2108 in Crohn's disease and ulcerative colitis, showing significant reductions in disease activity and inflammation. These early-stage results support the drug's mechanism and progression to larger Phase 2 studies, indicating potential for a new oral treatment in inflammatory bowel diseases.

Palisade Bio announced the presentation of clinical and translational findings for PALI-2108 at United European Gastroenterology Week. The key takeaway is the positive Phase 1b data for Crohn's disease, showing a 47.5% reduction in mean endoscopic disease activity and a 58.8% reduction in mean fecal calprotectin in a small cohort. Additionally, the drug showed early clinical activity in ulcerative colitis. This matters because it provides further validation for PALI-2108's mechanism of action and its potential as a once-daily oral treatment for inflammatory bowel diseases. For traders, this is a positive development for PALI in the short term, as it de-risks the asset somewhat and supports its progression into larger Phase 2 studies. The long-term implication is the potential for a significant new drug in a large market, but it's crucial to remember these are small, open-label, exploratory studies requiring confirmation in larger, controlled trials.

$PALI positive Positive early clinical trial results
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.